-
2024-519928-24-00
4
2025-08-21
Myelodysplastic Syndrome
-
2024-514954-63-00
9
2025-08-20
RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2024-516780-93-00
5
2025-07-09
Sustained immunosuppression
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-519052-82-00
4
2025-06-30
pleural mesothelioma
-
2024-517325-43-00
4
2025-06-19
multiple myeloma
-
2023-509788-25-00
6
2025-06-16
Rheumatoid arthritis
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2023-508773-82-00
5
2025-05-06
Stage IIB-IIIB (N2) resectable non small cell lung cancer
-
2024-517582-16-00
5
2025-04-14
rapid sequence induction in the operating room
-
2024-512496-12-00
5
2025-04-01
Moderate to Severe Plaque Psoriasis
-
2024-511442-39-00
5
2025-02-05
Rheumatoid arthritis (RA)
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2024-516109-21-00
5
2024-12-09
Polycythaemia Vera (PV)
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)
-
2024-513098-31-00
4
2024-11-14
Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
2024-514886-21-00
6
2024-11-06
Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus
(P
-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-516101-23-00
5
2024-10-28
Sarcoidosis
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma